| 2024-11-08 |
Stat Bite: Percent of Current Smokers Among Adults in the United States |
|
|
| 2024-11-08 |
Correction to: Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013–2015) |
|
|
| 2024-11-08 |
RE: Prevalence of cancer survivors in the United States |
|
|
| 2024-11-08 |
Celebrating the 1945 JNCI pioneering contribution to antiangiogenic therapy for cancer |
|
|
| 2024-11-08 |
Reducing ovarian cancer mortality through screening: an impossible dream? |
|
|
| 2024-11-08 |
Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key |
|
|
| 2024-11-08 |
Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors |
|
|
| 2024-11-08 |
Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes |
|
|
| 2024-11-08 |
Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework |
|
|
| 2024-11-08 |
An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer |
|
|
| 2024-11-08 |
Prevalence of cancer survivors in the United States |
|
|
| 2024-11-08 |
Older adults with cancer and common comorbidities—challenges and opportunities in improving their cancer treatment outcomes |
|
|
| 2024-11-08 |
ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities |
|
|
| 2024-11-08 |
Personalized starting age of gastric cancer screening based on individuals’ risk profiles: a population-based, prospective study |
|
|
| 2024-11-08 |
Ovarian cancer risk factors in relation to family history |
|
|
| 2024-11-08 |
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium |
|
|
| 2024-11-08 |
Using neurocognitive phenotypes to inform interventions for adult survivors of childhood cancer |
|
|
| 2024-11-08 |
Racial discrimination and health-care system trust among American adults with and without cancer |
|
|
| 2024-11-08 |
Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers |
|
|
| 2024-11-08 |
Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy |
|
|
| 2024-11-08 |
Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort |
|
|
| 2024-11-08 |
Comparing characteristics of individuals screened for lung cancer with 2021 vs 2013 US Preventive Services Task Force recommendations |
|
|
| 2024-11-08 |
Effect of smoking on melanoma incidence: a systematic review with meta-analysis |
|
|
| 2024-10-09 |
Stat Bite: Maternal orphans due to cancer worldwide in 2020 |
|
|
| 2024-10-09 |
Retraction and Replacement of: Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening |
|
|
| 2024-10-09 |
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening |
|
|
| 2024-10-09 |
Correction to: Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer |
|
|
| 2024-10-09 |
The “PRO”mise and “PRO”gress of PROs in cancer clinical trials |
|
|
| 2024-10-09 |
Continued prioritization of biomedical research over sociomedical research may widen disparities in cancer outcomes |
|
|
| 2024-10-09 |
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children’s Oncology Group report |
|
|
| 2024-10-09 |
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study |
|
|
| 2024-10-09 |
Differences in tumor-associated T-cell receptor repertoires between early-onset and average-onset colorectal cancer |
|
|
| 2024-10-09 |
Predicting prostate cancer grade reclassification on active surveillance using a deep learning–based grading algorithm |
|
|
| 2024-10-09 |
Metabolic Dysregulation and Cancer Risk Program (MeDOC): a transdisciplinary approach to obesity-associated cancers |
|
|
| 2024-10-09 |
Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis |
|
|
| 2024-10-09 |
The state of cancer-focused community outreach and engagement (COE): reflections of Black COE directors |
|
|
| 2024-10-09 |
Resource requirements to accelerate clinical applications of next-generation sequencing and radiomics: workshop commentary and review |
|
|
| 2024-10-09 |
RET overexpression leads to increased brain metastatic competency in luminal breast cancer |
|
|
| 2024-10-09 |
Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study |
|
|
| 2024-10-09 |
Characteristics of a cost-effective blood test for colorectal cancer screening |
|
|
| 2024-10-09 |
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research |
|
|
| 2024-10-09 |
BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression |
|
|
| 2024-10-09 |
Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor–positive breast cancer |
|
|
| 2024-10-09 |
Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival |
|
|
| 2024-10-09 |
Racial and socioeconomic disparities in survival among patients with metastatic non–small cell lung cancer |
|
|
| 2024-09-06 |
Stat Bite: Cancer of the Corpus and Uterus 5-Year Survival by Race and Ethnicity and Stage |
|
|
| 2024-09-06 |
Reviewers |
|
|
| 2024-09-06 |
Correction to: Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome |
|
|
| 2024-09-06 |
The utility of value frameworks in cost communications: making them real for patients |
|
|
| 2024-09-06 |
Improving our understanding of the complex relationship between cancer-related cognitive decline and Alzheimer’s disease |
|
|
| 2024-09-06 |
RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma? |
|
|
| 2024-09-06 |
RE: Spatial intratumor heterogeneity of programmed cell death ligand 1 expression predicts poor prognosis in resected non–small cell lung cancer |
|
|
| 2024-09-06 |
Response to Wu and Zhang |
|
|
| 2024-09-06 |
Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035 |
|
|
| 2024-09-06 |
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities |
|
|
| 2024-09-06 |
Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence |
|
|
| 2024-09-06 |
The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality |
|
|
| 2024-09-06 |
Alzheimer disease–related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study |
|
|
| 2024-09-06 |
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208) |
|
|
| 2024-09-06 |
Association between oral targeted cancer drug net health benefit, uptake, and spending |
|
|
| 2024-09-06 |
Health insurance among survivors of childhood cancer following Affordable Care Act implementation |
|
|
| 2024-09-06 |
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists |
|
|
| 2024-09-06 |
Recent and projected incidence trends and risk of anal cancer among people with HIV in North America |
|
|
| 2024-09-06 |
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) |
|
|
| 2024-09-06 |
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease |
|
|
| 2024-08-08 |
Stat Bite: The most frequent five cancers diagnosed worldwide, and the most frequent cancer diagnosed in each of 185 countries among males aged 15-34 years in 2022 |
|
|
| 2024-08-08 |
Correction to: Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial |
|
|
| 2024-08-08 |
Correction to: In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine |
|
|
| 2024-08-08 |
Editor’s Note to: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex |
|
|
| 2024-08-08 |
Correction to: Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial |
|
|
| 2024-08-08 |
When the somatic genome informs the germline: the example of TP53 |
|
|
| 2024-08-08 |
RE: Dietary interventions in cancer: a systematic review of all randomized controlled trials |
|
|
| 2024-08-08 |
RE: Association of metformin use and cancer incidence: a systematic review and meta-analysis |
|
|
| 2024-08-08 |
Response to Khouri and Suissa |
|
|
| 2024-08-08 |
Dietary interventions, statistical power, and unanswered questions |
|
|
| 2024-08-08 |
Time to change the paradigm for primary endpoints in cancer screening trials? |
|
|
| 2024-08-08 |
RE: The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis |
|
|
| 2024-08-08 |
Response to Shamsi, Hina, Akhtar, et al. |
|
|
| 2024-08-08 |
Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors |
|
|
| 2024-08-08 |
Executing plans to enhance diversity across cancer centers in the United States: opportunities and challenges |
|
|
| 2024-08-08 |
Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence |
|
|
| 2024-08-08 |
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act |
|
|
| 2024-08-08 |
Prediagnostic plasma proteomics profile for hepatocellular carcinoma |
|
|
| 2024-08-08 |
Expanding active living after cancer to underserved cancer survivors and their caregivers |
|
|
| 2024-08-08 |
Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities |
|
|
| 2024-08-08 |
The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review |
|
|
| 2024-08-08 |
Growing the global cancer care system: success stories from around the world and lessons for the future |
|
|
| 2024-08-08 |
The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17 |
|
|
| 2024-08-08 |
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer |
|
|
| 2024-08-08 |
Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinoma |
|
|
| 2024-08-08 |
Adolescents and young adults with cancer: the clinical course of COVID-19 infections |
|
|
| 2024-08-08 |
A population-based study of COVID-19 mortality risk in US cancer patients |
|
|
| 2024-08-08 |
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening |
|
|
| 2024-08-08 |
Evaluating colonoscopy quality by performing provider type |
|
|
| 2024-08-08 |
Housing assistance among patients with cancer: SEER-Medicare US Department of Housing and Urban Development data linkage |
|
|
| 2024-08-08 |
Alcohol and colorectal cancer risk, subclassified by mutational signatures of DNA mismatch repair deficiency |
|
|
| 2024-08-08 |
TP53-associated early breast cancer: new observations from a large cohort |
|
|
| 2024-08-08 |
Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment |
|
|
| 2024-08-08 |
Advancing health equity in cancer survivorship research: National Institutes of Health 2017–2022 portfolio review |
|
|
| 2024-08-08 |
Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study |
|
|
